Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), and SelectHealth, a Utah based not-for-profit health plan and wholly owned subsidiary of Intermountain Healthcare, announced today that reSET-O®, the only FDA- authorized PDT to treat opioid use disorder (OUD), has been added as a covered benefit for SelectHealth’s members. SelectHealth serves more than one million members across Utah, Idaho, and Nevada.

“Both organizations are focused on keeping people healthy and providing high-value care that is accessible throughout the communities that we serve,” said H. Eric Cannon, Chief Pharmacy Benefits Officer at SelectHealth. “This move to provide access is vital to the treatment of opioid use disorder and highlights another example of our commitment to clinical programs that improve outcomes and embrace innovation.”

reSET-O is an innovative response to the ongoing opioid crisis in America. In Utah specifically, ten adults die each week from drug overdose, eight of which are a result of opioids, with Utahns particularly affected by prescription opioids1. The White House recently released its National Drug Control Strategy that outlines the administration’s comprehensive path forward to address the addiction crisis, noting that, for the first time in our Nation’s history we have passed the tragic milestone of 100,000 deaths resulting from drug overdoses in a 12-month period2. The strategy outlines ways to expand access to evidence-based prevention, harm reduction, treatment, and recovery services, including evidence-based motivational incentives such as contingency management and FDA-cleared digital tools that enable treatment.

“With the opioid epidemic impacting more people than ever across the country, we applaud SelectHealth for its leadership in being the first in the state of Utah to provide patients seeking recovery coverage of innovative FDA-authorized treatment delivered through their mobile devices when and where they need it most,” said Julia Strandberg, Chief Commercial Officer at Pear Therapeutics. “Together, we can help improve access to safe and effective treatment options for those suffering from addiction.”

PDTs are an innovative therapeutic class that uses software to directly treat disease. reSET-O has been measured in real-world use and its therapeutic content studied in a randomized controlled trial, with results published in a peer-reviewed medical journal3. Pear recently released publications showing the potential for improved real-world health outcomes and decreased healthcare resource utilization for patients using reSET-O4-13. Used in combination with transmucosal buprenorphine, reSET-O is adjunctive to outpatient care, provide patients with cognitive behavioral therapy, fluency training, and contingency management, while clinicians receive access to clinical dashboards to inform in-office and tele visits.

Exit mobile version